Penyakit Parkinson : Tinjauan Terpadu Biomedis dan Kemajuan Terapi Terkini

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta, which plays a crucial role in regulating movement. The hallmark pathology of PD is the formation of Lewy bodies, abnormal protein aggregates composed primarily of α-synuclein. The pathophysiological mechanisms of this disease are multifactorial, involving a complex interaction between genetic and environmental factors. Molecularly, several key mechanisms involved include mitochondrial dysfunction, oxidative stress, chronic neuroinflammation, and genetic mutations in the LRRK2, DJ-1, PINK1, and SNCA genes, which have been shown to influence susceptibility to PD. In addition to genetic factors, the risk of developing PD is also influenced by environmental exposures, including pesticides, heavy metals, and exposure to certain toxins that can accelerate neuronal damage. The clinical manifestations of PD are characterized by classic motor symptoms, namely resting tremor, bradykinesia, rigidity, and gait disturbances, which are often accompanied by non-motor symptoms such as sleep disturbances, depression, autonomic dysfunction, and cognitive decline. Diagnosis generally follows the UK Brain Bank clinical criteria, supported by neuroimaging techniques such as DaTSCAN and MRI, and the development of biomarkers based on α-synuclein detection to improve the accuracy of early diagnosis. The main treatment option currently is pharmacological therapy, particularly levodopa, often combined with dopamine agonists or MAO-B inhibitors to optimize symptom control. In advanced cases, surgery in the form of deep brain stimulation can provide significant improvement. Innovative therapies such as gene therapy, stem cell therapy, and the integration of wearable devices and artificial intelligence are being developed to improve symptom monitoring and personalize treatment. Current research focuses on the development of more sensitive diagnostic methods and neuroprotective therapies that can slow disease progression.

Authors

Publication Details

Journal
Jurnal Kesehatan Amanah
Published
2025-09-15
DOI
https://doi.org/10.57214/jka.v9i2.914
Primary Topic
Public Health and Nutrition
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Penyakit Parkinson : Tinjauan Terpadu Biomedis dan Kemajuan Terapi Terkini

Triyana Sari, Sari Mariyati Dewi Nataprawira, Erick Sidarta
Jurnal Kesehatan Amanah
Public Health and Nutrition
article

Penyakit Parkinson : Tinjauan Terpadu Biomedis dan Kemajuan Terapi Terkini

Triyana Sari, Sari Mariyati Dewi Nataprawira, Erick Sidarta
article en

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta, which plays a crucial role in regulating movement. The hallmark pathology of PD is the formation of Lewy bodies, abnormal protein aggregates composed primarily of α-synuclein. The pathophysiological mechanisms of this disease are multifactorial, involving a complex interaction between genetic and environmental factors. Molecularly, several key mechanisms involved include mitochondrial dysfunction, oxidative stress, chronic neuroinflammation, and genetic mutations in the LRRK2, DJ-1, PINK1, and SNCA genes, which have been shown to influence susceptibility to PD. In addition to genetic factors, the risk of developing PD is also influenced by environmental exposures, including pesticides, heavy metals, and exposure to certain toxins that can accelerate neuronal damage. The clinical manifestations of PD are characterized by classic motor symptoms, namely resting tremor, bradykinesia, rigidity, and gait disturbances, which are often accompanied by non-motor symptoms such as sleep disturbances, depression, autonomic dysfunction, and cognitive decline. Diagnosis generally follows the UK Brain Bank clinical criteria, supported by neuroimaging techniques such as DaTSCAN and MRI, and the development of biomarkers based on α-synuclein detection to improve the accuracy of early diagnosis. The main treatment option currently is pharmacological therapy, particularly levodopa, often combined with dopamine agonists or MAO-B inhibitors to optimize symptom control. In advanced cases, surgery in the form of deep brain stimulation can provide significant improvement. Innovative therapies such as gene therapy, stem cell therapy, and the integration of wearable devices and artificial intelligence are being developed to improve symptom monitoring and personalize treatment. Current research focuses on the development of more sensitive diagnostic methods and neuroprotective therapies that can slow disease progression.

Jurnal Kesehatan AmanahVol. 9(2)
Openalex Percentile: Top 59%
Public Health and Nutrition
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.